J Nephropathol. 2019;8(4):45-45.
doi: 10.15171/jnp.2019.45
  Abstract View: 75
  PDF Download: 46

Review Article

Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review

Mohsen Akhavan Sepahi 1 * ORCiD, Sarvenaz Mehrabi 2 ORCiD, Rohollah Valizadeh 3 ORCiD, Steven James Kellner 4, Azin Mirzazadeh 5 ORCiD, Semko Ebrahimi 6 ORCiD

1 Department of Pediatric Nephrology, School of Medicine and Pediatric Clinical Research of Development Center, Qom University of Medical Sciences, Qom, Iran
2 11Walmer Gardens, N6G4H4, London, Ontario, Canada
3 Department of Epidemiology, Student Research Committee, School of Public Health, Iran University of Medical science, Tehran, Iran
4 Head International Research and Development, Mesencell Biotech International Ltd, 20-22 Wenlock Road, London, N1 7GU, United Kingdom
5 Joint Bioinformatics Graduate Program, University of Arkansas Little Rock and University of Arkansas for Medical Sciences, Little Rock, AR, USA
6 Department of Anesthesiology, Health North gGmbH Klinikverbund Bremen, Hospital left of the Weser (klinkum Links der Weser) (Senator-Weßling-Straße 1; 28277), Bremen, Germany
*Corresponding author: Mohsen Akhavan Sepahi, Email: Email: akhavansepahim@yahoo.com

Abstract

Chemotherapy has been accepted as the most common choice for cancer treatment. However, chemotherapy-induced toxicity and chemotherapy resistance are the two challenging barriers to the treatment. Metformin is a safe, inexpensive, and the first line drug to treat type II diabetes. It has also a significant anti-tumor effect with a selective cytotoxic efficacy on cancer stem cells. It also has renoprotective efficacy. The current study contributes to incorporating metformin to chemotherapeutic agents to develop treatment efficiency and reduce the chemotherapy-induced side-effects (such as toxicity and resistance) and also to benefit the nephroprotective impact of this drug.

Implication for health policy/practice/research/medical education:

The current study contributes to incorporating metformin with frequently prescribed chemotherapeutic agents to develop treatment efficiency and reduce the chemotherapy-induced side-effects (such as toxicity and resistance), preventing cell proliferation, tumor growth, angiogenesis, metastasis, simulating apoptosis, targeting NF-κB pathway, nephroprotection and anti-oxidant activity.

Please cite this paper as: Akhavan Sepahi M, Mehrabi S, Valizadeh R, Kellner SJ, Mirzazadeh A, Ebrahimi S. Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review. J Nephropathol. 2019;8(4):e45. DOI: 10.15171/ jnp.2019.45.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 75

Your browser does not support the canvas element.


PDF Downloaded: 46

Your browser does not support the canvas element.

Submitted: 07 Aug 2019
Accepted: 02 Oct 2019
First published online: 20 Oct 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)